A phase III randomised, double-blind trial of immunotherapy with a polyvalent melanoma vaccine (C-VAX) [Canvaxin; cancer vaccine] plus Bacille Calmette-Guerin (BCG) versus placebo plus BCG as a post surgical treatment for stage IV melanoma

Trial Profile

A phase III randomised, double-blind trial of immunotherapy with a polyvalent melanoma vaccine (C-VAX) [Canvaxin; cancer vaccine] plus Bacille Calmette-Guerin (BCG) versus placebo plus BCG as a post surgical treatment for stage IV melanoma

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2009

At a glance

  • Drugs Cancer vaccine (Primary) ; BCG
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Aug 2009 Actual end date (Aug 2003) added as reported by ISRCTN: Current Controlled Trials record.
    • 13 Aug 2009 Actual initiation date (1 Apr 1999), lead trial centres added as reported by ISRCTN: Current Controlled Trials record.
    • 01 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top